Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday Nov 23, 2009

DrStockPick.com Stock Report!

PWRM, STEM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

Chelsea Therapeutics International (NASDAQ:CHTP) said its drug Droxidopa has a benefit for five neurological disorder symptoms. CHTP will continue to further investigate these benefits even though last week Chelsea announced the drug did not meet its primary endpoints of the trial.

Blame this failure to meet the primary endpoints on a poor trial design and the higher than anticipated placebo response. Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, says they will have a more comprehensive review of the studies data to determine what effects the higher placebo effects had and also look for other contributing factors.

Shares surged today over 20% on the positive news but it still comes nowhere close to making up for the 61% drop CHTP experienced when Droxidopa did not meet its endpoints.

Chelsea will have a better

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The